Loading...
Loading...
ACADIA Pharmaceuticals
ACAD today
announced that it has initiated a Phase II feasibility trial designed to
examine the efficacy and safety of pimavanserin as a treatment for
patients with Alzheimer's disease psychosis (ADP). No drug is approved
in the United States to treat ADP and the off-label use of current
antipsychotics is linked to increased mortality, serious adverse events,
and cognitive decline in elderly patients with dementia-related
psychosis.
“The development of psychosis and related behavioral disturbances in
patients with Alzheimer's disease carries a poor prognosis and often has
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in